- Transaction strengthens QIAGEN’s leadership position in automated molecular testing
- QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million
- Medium- and high-throughput NeuMoDx automation solutions based on PCR testing technology to now be integrated into QIAGEN’s portfolio on a global basis
- Menu of test solutions for infectious diseases – which already includes COVID-19 – to be expanded, especially in the U.S.
HILDEN, Germany & ANN ARBOR, Mich.–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology.
The transaction was completed after QIAGEN received U.S. regulatory clearance for the full acquisition. In 2018, QIAGEN had purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million. The final payment price for this remaining stake includes customary purchase price adjustments for cash, indebtedness and transaction costs. Also as part of the 2018 agreement, QIAGEN has distributed the high-throughput NeuMoDx™ 288 and the medium-throughput NeuMoDx™ 96 platforms in Europe and other markets outside the U.S.
“NeuMoDx’s automated molecular testing platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics assays, including laboratory-developed tests,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand QIAGEN’s portfolio of automated testing solutions and provide another driver for future growth.”
“NeuMoDx devices offer labs with medium to high throughput exactly what they need,” Bernard added. “Labs want compact systems with true random access, fast turnaround time, full automation and comprehensive menus. The full integration of the NeuMoDx systems will allow QIAGEN to address laboratory needs in almost any setting for molecular diagnostics. We are excited to be able to build on NeuMoDx’s success and will jointly work on expanding our product portfolio and global distribution.”
Please find the full press release here
Contacts
Investor Relations
John Gilardi +49 2103 29 11711
Phoebe Loh +49 2103 29 11457
ir@QIAGEN.com
Public Relations
Thomas Theuringer +49 2103 29 11826
pr@QIAGEN.com
